Congrats to all the new heme/onc fellows joining the best specialty this week!! . This week’s episode focuses on how to prepare for the start of heme/onc fellowship - differences from residency, how to succeed, research & study tips, resources….

The answer is D) MIRV is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC).

After a few #ASCO25 updates, we are back this week with a re-do for Ovarian CA (last recorded in 2022). One 🆕 update is the approval of Mirvetuximab Sorvtansine (MIRV) for platinum-refractory ovarian CA. What target is needed for use of MIRV?. @HemOncFellows.

RT @AaronGoodman33: Med Twitter is alive and well. Amazing critical appraisal of an amazing trial. You can learn a lot from reading this.

RT @DrKarineTawagi: #AMPLITUDE: role of PARPi in mCSPC?. ➡️for fellows: PARPi only approved in mCRPC currently. 🚹nira + abi in pts w/ HRRm….

RT @FaltasLab: Grateful for the opportunity to present our CLONEVO investigator-initiated trial (IIT) in bladder cancer at @ASCO #ASCO2025.….

RT @BianchiniGP: 🔥 #ASCO25 T-DXd/pertuzumab better than THP (@stolaney1) .Expected superpositive results from DB09. Clearly best option for….

RT @fitaftercancer: Standing ovation at ⁦@ASCO⁩ for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise ef….

RT @rmistry91: So proud of this study and honored to be the senior author! . What we’ve learned: @TheFellowOnCall and @TwoOncDocs should be….

RT @AnaVManana: 📢 #ASCOTrainee Come join us at 1:00pm to learn all the tips about finding your first job!.It will be a wonderful panel with….

@HemOncFellows.

Important late-breakfast abstract #DESTINYBREAST09 . For fellows ➡️ current SOC for HER2+ MBC is THP or DHP (taxane + trastuzumab + pertuzumab.➡️ HER2+ = IHC2+ with +FISH or 3+. ❓# in control arm w/ TDxD at progression.❓sequencing.❓long-term TdXd more toxic then HP. #ASCO25.

RT @AaronGoodman33: The fact this was NOT a plenary at ASCO clearly demonstrates pharma’s strong influence over academic oncology in my opi….

🚨NEW SOC 🚨.#MATTERHORN: P3 durvalumab+ FLOT in resectable GC/GEJC. For fellow ➡️ current SOC is periop FLOT (5FU oxali taxol) . 🔹D + FLOT mEFS was NR vs 32.8 mo with P + FLOT.🔹 mOS was NR for D + FLOT vs 47.2 mo for P + FLOT.🔸D+ FLOT did not delay surgery or adj tx

RT @ACortelliniMD: WAIT A MINUTE!.we're all for science, research and networking, but I met #Milliethedog, officially appointed by @ASCO!.S….

Takeaways: it is not yet approved & OS data is not yet available, unlikely to show up on boards or MCQs at this time.

#SERENA6 and how it fits in to current landscape for fellows 💡 . ➡️1L HR+ HER-2 (-) MBC SOC: CDK4/6 + AI or fulvestrant- here most pts received palbociclib - at least 6mo. ESR1 detected on ctDNA AHEAD of progression & if detected added Camizestrant (oral SERD) ➡️met PFS. #ASCO25

#ATOMIC phase 3 trial: stage 3 CRC adjuvant Atezolizumab + FOLFOX vs FOLFOX . For fellows ➡️where it fits in to current practice . All pts need MMR testing! 10-15% localized CRC are dMMR . 🌟 new SOC 10% improvement in 3yr DFS but also good results for neoadj IO #NICHE2 . #ASCO25

Plenary at 1PM in hall B1!. 🌟 #VERIFY rusfertide for PV. 🌟 #NIVOPOSTOP: nivolumab post chemo-RT in H&N. 🌟 chemo adj atezo for st3 deficient dMMR CRC. 🌟 #SERENA6 Camizestrant, a novel SERD + CDK4/6 in MBC. 🌟 #MATTERHORN: durvalumab + FLOT in gastric/GEJ . @ASCO #ASCO25.

Starting now! Impt info on applying to fellowship 🌟 @ASCOTECAG @HemOncFellows.